Bayesian Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bayesian Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,100	Closed	-$1.24M	–	725
2021 Q1	$1.24M	Buy	8,100 +4,200	+108%	+$650K	0.29%	92
2020 Q4	$609K	Buy	+3,900	New	+$501K	0.16%	183
2020 Q3	–	Sell	-3,009	Closed	-$338K	–	760
2020 Q2	$338K	Sell	3,009 -8,637	-74%	-$917K	0.07%	324
2020 Q1	$1.05M	Buy	11,646 +8,146	+233%	+$799K	0.23%	122
2019 Q4	$379K	Sell	3,500 -3,577	-51%	-$383K	0.06%	364
2019 Q3	$693K	Buy	+7,077	New	+$798K	0.13%	214
2019 Q1	–	Sell	-5,611	Closed	-$546K	–	823
2018 Q4	$546K	Buy	+5,611	New	+$663K	0.11%	261
2017 Q4	–	Sell	-9,300	Closed	-$1.3M	–	779
2017 Q3	$1.3M	Buy	+9,300	New	+$1.26M	0.31%	96
2017 Q1	–	Sell	-6,282	Closed	-$769K	–	765
2016 Q4	$769K	Buy	6,282 +1,082	+21%	+$132K	0.19%	198
2016 Q3	$637K	Buy	+5,200	New	+$669K	0.42%	75

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Bayesian Capital Management's ALXN Position: Q2 2021 in Review

Bayesian Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 8,100 shares — an estimated $1.24M sold.

Bayesian Capital Management first reported a position in ALXN in Q3 2016 and held it in 10 quarters. The position peaked at $1.3M in Q3 2017. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Bayesian Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Bayesian Capital Management sold 8,100 Alexion Pharmaceuticals shares in Q2 2021, an estimated $1.24M.
Bayesian Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 10 quarters.
Bayesian Capital Management's Alexion Pharmaceuticals position peaked at $1.3M in Q3 2017.
710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Bayesian Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.